Bucladesine sodium [16980-89-5]
Cat# NB-64-05685-2g
Size : 2g
Brand : Neo Biotech
Bucladesine sodium
Alias Sodium dibutyryl cAMP, Dibutyryl-cAMP sodium salt, Dibutyryl-cAMP, DC2797, dbcAMP, Bucladesine sodium salt, Bucladesine
Bucladesine sodium (DC2797) is a cAMP analog with cell-permeable properties. Bucladesine sodium is also a cAMP-dependent protein kinase (PKA) activator and a phosphodiester (PDE) inhibitor. Bucladesine sodium has anti-inflammatory activity.
Product Introduction
Bioactivity
Chemical Properties
Storage & Solubility Information
| Description | Bucladesine sodium (DC2797) is a cAMP analog with cell-permeable properties. Bucladesine sodium is also a cAMP-dependent protein kinase (PKA) activator and a phosphodiester (PDE) inhibitor. Bucladesine sodium has anti-inflammatory activity. |
| In vitro | METHODS: Human eosinophil EoL-1 cells were treated with Bucladesine sodium (10-100 µM) for 8 days and activity was measured using PKA assay. RESULTS: Proliferation of EoL-1 cells treated with Bucladesine sodium increased in a time-dependent manner. [1] METHODS: PC12 cells were treated with Bucladesine sodium (1 mM) for 72 h. TNF-α levels were measured by ELISA assay. RESULTS: Bucladesine sodium increased the activity of PKA. [2] |
| In vivo | METHODS: To study the anti-inflammatory activity in vivo, Bucladesine sodium (0.24-0.7 µg/kg) was administered intraperitoneally to a mouse model of copper pine demyelination once daily for seven days. RESULTS: Bucladesine had a protective effect on myelin formation. Enhanced intracellular cAMP prevented demyelination and exerted anti-inflammatory and anti-apoptotic properties in a mouse model of copper pine demyelination. [3] METHODS: To investigate the effects on liver injury, Bucladesine sodium (0.5-500 mg/kg) was intraperitoneally injected into C57BL/6J jcl mice, and liver injury was induced by the intravenous injection of rTNF-α (1.0 µg/kg) and intraperitoneal injection of D-gal (500 mg/kg) after 1 h. The RESULTS showed that Bucladesine protected against hepatic injury in C57BL/6J jcl mice. RESULTS: Bucladesine protected mice from TNF-α/D-gal-induced liver injury.Bucladesine significantly enhanced the expression of Hsp70 in hepatocytes of D-gal/TNFα-injected mice, which was closely related to the inhibition of liver injury. [4] |
| Animal Research | Animal: Mice. Formulation: water/DMSO (9:1). Dosages: 600 nM. Administration: i.p. |
| Synonyms | Sodium dibutyryl cAMP, Dibutyryl-cAMP sodium salt, Dibutyryl-cAMP, DC2797, dbcAMP, Bucladesine sodium salt, Bucladesine |
| Molecular Weight | 491.37 |
| Formula | C18H23N5NaO8P |
| Cas No. | 16980-89-5 |
| Smiles | [NaH].CCCC(=O)Nc1ncnc2n(cnc12)[C@@H]1O[C@@H]2COP(O)(=O)O[C@H]2[C@H]1OC(=O)CCC |
| Relative Density. | no data available |
| Color | White |
| Appearance | Solid |
| Storage | store at low temperature,keep away from moisture,keep away from direct sunlight | Powder: -20°C for 3 years | In solvent: -80°C for 1 year | Shipping with blue ice/Shipping at ambient temperature. | |||||||||||||||||||||||||||||||||||
| Solubility Information | H2O: 200 mg/mL (407.03 mM), Sonication is recommended.  DMSO: 144 mg/mL (293.06 mM), Sonication is recommended. | |||||||||||||||||||||||||||||||||||
| In Vivo Formulation | 10% DMSO+40% PEG300+5% Tween 80+45% Saline: 4 mg/mL (8.14 mM), Sonication is recommended. Please add the solvents sequentially, clarifying the solution as much as possible before adding the next one. Dissolve by heating and/or sonication if necessary. Working solution is recommended to be prepared and used immediately. The formulation provided above is for reference purposes only. In vivo formulations may vary and should be modified based on specific experimental conditions. | |||||||||||||||||||||||||||||||||||
Solution Preparation Table | ||||||||||||||||||||||||||||||||||||
DMSO/H2O
| ||||||||||||||||||||||||||||||||||||
You might also be interested by the following products:
Cat#
Description
Cond.
Price Bef. VAT